| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198675 | Journal of Allergy and Clinical Immunology | 2012 | 19 Pages |
Abstract
Our data suggest that IL-17 is a key “driver” cytokine that activates pathogenic inflammation in subjects with psoriasis. Neutralizing IL-17 with ixekizumab might be a successful therapeutic strategy in psoriasis.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
James G. MD, Scott MD, Mayte PhD, Patrick A. MB, BS, Krista M. Phipps, Gregory S. PhD, Juliet MD, Artemis Katcherian, Inna Cueto, Traci White, Subhashis MD, Robert W. DO,